Orphan Drug Consulting

Orphan Drug Consulting supports new and emerging pharmaceutical companies to launch products globally from an EU and US location.

[Orphan Drug Consulting @OrphanDrugIRE]

The Orphan Drug Consulting team was proud to be raising awareness for Rare Disease Day yesterday by showing their colours and stripes.

See our video below for more information about rare diseases.

#Shareyourcolours #Showyourstripes #Rarediseaseday2023

[Orphan Drug Consulting @OrphanDrugIRE]

Did you know there are 300 million people worldwide living with a rare disease?

This equates to between 3.5% and 5.9% of the global population.

See how you can get involved this Rare Disease Day by clicking on the link below.
https://t.co/TVh7rKpTCc

#Rarediseaseday

[Orphan Drug Consulting @OrphanDrugIRE]

With #RareDiseaseDay just passed, we are proud to work with innovative companies focused on the unmet needs of so many people suffering from these conditions worldwide. Read more about rare diseases and the role orphan drugs play in their treatment here:

https://t.co/UV6OaA4vR7

[Orphan Drug Consulting @OrphanDrugIRE]

For the first time, an AI-developed drug has entered into clinical trials. DSP-1181 saw a substantially shortened the length of time in preclinical development. Does this represent a more efficient way of conducting preclinical research? https://t.co/MdG77gjAKt

[Orphan Drug Consulting @OrphanDrugIRE]

Orphan Drug Consulting Launches New Website!
Orphan Drug Consulting are delighted to launch our new website. With new contact pages, expanded service information and upcoming event scheduling, check out our new page at https://t.co/OqUtgMLuM7

[Akcea Therapeutics @akceatx]

Together with @ionispharma , we are pleased to announce we have received approval of our investigational therapy for familial #chylomicronemia syndrome (FCS) in the EU. See our news announcement: https://t.co/FPUMwNE3ap

[Orphan Drug Consulting @OrphanDrugIRE]

Congratulations to our colleagues @akceatx on this important milestone. Looking forward to working together to achieve a successful EU launch. @consultevelyn

[Akcea Therapeutics @akceatx]

Together with @ionispharma, today we announced a positive EU #CHMP opinion for our investigational therapy for familial #chylomicronemia syndrome. As we reflect on #RareDiseaseDay, we want to highlight what an important moment this is for the FCS community.https://t.co/T7IqWdXXpC